The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease
Abstract
While significantly reduced glucose metabolism in fronto-temporo-parietal and cingulate cortices has been demonstrated in Alzheimer's disease (AD) compared with controls, cerebral glucose metabolism in patients with mild cognitive impairment who subsequently develop AD is less well-defined. In the present study we measured cerebral glucose metabolism by positron emission tomography (PET) with (18)F-2-fluoro-2-deoxy-D-glucose in 14 patients with aging-associated cognitive decline (AACD), 44 patients with AD, and 14 healthy control subjects at baseline. The AACD patients were clinically followed up, and conversion to AD was determined. Compared with controls, AACD patients had significantly reduced glucose metabolism in the right precuneus, posterior cingulate, right angular gyrus, and bilateral middle temporal cortices, while the respective deficits were more pronounced in AD patients and also involved the frontal cortices. AACD patients who subsequently converted to AD (AACD-converters) showed more extended metabolic changes which also involved the frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Individuals with MCI and early AD have diminished regional brain uptake of 2-DG, as measured by FDG-PET, before MCI-AD conversion, brain atrophy, or neurodegenerative changes (268, 345, 424, 425, 517).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [268]
In the citing paper
“late-onset, sporadic AD is characterized with an early loss of BBB transporters including GLUT1 transporter for glucose (268, 424, 425, 345, 517)”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [268]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Preclinical prediction of Alzheimer's disease using SPECT
Johnson, K. A., Jones, K., Holman, B. L., Becker, J. A., Spiers, P. A., Satlin, A., & Albert, M. S. (1998) · Neurology · doi:10.1212/wnl.50.6.1563 · Cited by 471
Nestor, P. J., Fryer, T. D., Ikeda, M., & Hodges, J. R. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02999.x · Cited by 227
Flagged first, then by citations
Research works printed but not linked: 34
- Arnaiz, 2001, Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment, NeuroReport, 12, 851, 10.1097/00001756-200103260-00045 · DOI · Paper page
- Buchsbaum, 1991, Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies, Archives of General Psychiatry, 48, 840, 10.1001/archpsyc.1991.01810330064010 · DOI
- Chételat, 2003, Mild cognitive impairment. Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?, Neurology, 60, 1374, 10.1212/01.WNL.0000055847.17752.E6 · DOI
- De Leon, 2001, Prediction of cognitive decline in normal elderly subjects with 2-(18F)-fluoro-2-deoxy-d-glucose/positron-emission-tomography (FDG/PET), Proceedings of the National Academy of Sciences of the United States of America, 98, 10966, 10.1073/pnas.191044198 · DOI · Paper page
- De Santi, 2001, Hippocampal formation glucose metabolism and volume losses in MCI and AD, Neurobiology of Aging, 22, 529, 10.1016/S0197-4580(01)00230-5 · DOI · Paper page
- Drzezga, 2003, Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study, European Journal of Nuclear Medicine and Molecular Imaging, 30, 1104, 10.1007/s00259-003-1194-1 · DOI
- Elias, 2000, The preclinical phase of Alzheimer disease. A 22-year prospective study of the Framingham cohort, Archives of Neurology, 57, 808, 10.1001/archneur.57.6.808 · DOI · Paper page
- Encinas, 2003, Regional blood flow assessed with 99mTc_ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease, European Journal of Nuclear Medicine and Molecular Imaging, 30, 1473, 10.1007/s00259-003-1277-z · DOI
- Folstein, 1975, ‘Mini mental state’. A practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- Friston, 1995, Statistical parametric maps in functional imaging: a general linear approach, Human Brain Mapping, 2, 189, 10.1002/hbm.460020402 · DOI · Paper page
- Hachinski, 1975, Cerebral blood flow in dementia, Archives of Neurology, 32, 632, 10.1001/archneur.1975.00490510088009 · DOI · Paper page
- Haxby, 1985, Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease, Journal of Cerebral Blood Flow and Metabolism, 5, 193, 10.1038/jcbfm.1985.25 · DOI
- Herholz, 2002, Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, NeuroImage, 17, 302, 10.1006/nimg.2002.1208 · DOI · Paper page
- Hsiung, 2004, Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging, CMAJ, 171, 863, 10.1503/cmaj.1031789 · DOI
- Huang, 2002, Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment, BMC (Biomedcentral) Neurology, 2, 9, 10.1186/1471-2377-2-9 · DOI
- Ishiwata, 1998, Cerebral blood flow of patients with age-associated memory impairment and the early stage of Alzheimer's disease. A study by SPECT using the ARG method, Nippon Ika Daigaku Zasshi, 65, 140, 10.1272/jnms1923.65.140 · DOI
- Levy, 1994, Aging-associated cognitive decline, International Psychogeriatrics, 6, 63, 10.1017/S1041610294001626 · DOI
- McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Nestor, 2004, Advances in the early detection of Alzheimer's disease, Nature Medicine, 10, S34, 10.1038/nrn1433 · DOI
- Okamura, 2000, Prediction of progression in patients with mild cognitive impairment using IMP-SPECT, Nippon Ronen Igakkai Zasshi, 37, 974, 10.3143/geriatrics.37.974 · DOI
- Pantel, 2002, Progressive medial temporal lobe changes in Alzheimer's disease revealed by quantitative MRI: potential use for monitoring of drug-related changes, Drug Development Research, 56, 51, 10.1002/ddr.10060 · DOI
- Pantel, 2003, Parahippocampal volume deficits in subjects with aging-associated cognitive decline, American Journal of Psychiatry, 160, 379, 10.1176/appi.ajp.160.2.379 · DOI
- Pantel, 2004, Distribution of cerebral atrophy as assessed by magnetic resonance imaging reflects patterns of neuropsychological deficits in Alzheimer's dementia, Neuroscience Letters, 361, 17, 10.1016/j.neulet.2003.12.072 · DOI
- Ravaglia, 2006, Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors, Dementia and Geriatric Cognitive Disorders, 21, 51, 10.1159/000089515 · DOI
- Ritchie, 2001, Classification criteria for mild cognitive impairment — a population-based validation study, Neurology, 56, 37, 10.1212/WNL.56.1.37 · DOI
- Scarmeas, 2004, Cognitive reserve: implications for diagnosis and prevention of Alzheimer's disease, Current Neurology and Neuroscience Reports, 4, 374, 10.1007/s11910-004-0084-7 · DOI
- Schönknecht, 2003, Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy, Psychiatry Research: Neuroimaging, 120, 231, 10.1016/S0165-1781(03)00197-5 · DOI
- Schönknecht, 2005, Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young–old subjects, American Journal of Psychiatry, 162, 2071, 10.1176/appi.ajp.162.11.2071 · DOI
- Schröder, 1998, Prevalence of mild cognitive impairment in a community sample, Journal of Neural Transmission Supplement, 54, 51, 10.1007/978-3-7091-7508-8_5 · DOI
- Schröder, 2001, Patterns of cortical activity and memory performance in Alzheimer's disease, Biological Psychiatry, 49, 426, 10.1016/S0006-3223(00)00983-5 · DOI
- Silverman, 2001, Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome, Journal of the American Medical Association, 286, 2110
- Staffen, 2005, Brain perfusion SPECT in patients with mild cognitive impairment and Alzheimer's disease: comparison of a semiquantitative and a visual evaluation, Journal of Neural Transmission, 286, 2110
- Tanaka, 2002, Regional cerebral blood flow abnormalities in nondemented patients with memory impairment, Journal of Neuroimaging, 12, 112, 10.1111/j.1552-6569.2002.tb00106.x · DOI
- Winblad, 2004, Mild cognitive impairment — beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment, Journal of Internal Medicine, 256, 240, 10.1111/j.1365-2796.2004.01380.x · DOI · Paper page
Cited by
Sorted by citations
Items 101–139 of 139
Braak neurofibrillary tangle staging prediction from in vivo MRI metrics
Dallaire‐Théroux, C., Beheshti, I., Potvin, O., Dieumegarde, L., Saïkali, S., Duchesne, S., & Initiative, A. D. N. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.07.001 · Cited by 16
Denis, P. A. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.09.008 · Cited by 10
“Breathing (or injection) of a 15N2 enriched air (resp. solute), then brain mapping of 15N2, using PET scanning, 15N2 being the radiotracer.”
BackgroundInfluentialIdentification of key lipid metabolism-related genes in Alzheimer’s disease
Zeng, Y., Cao, S., Li, N., Tang, J., & Lin, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01918-9 · Cited by 18
“Changes in energy metabolism have been linked to AD progression [43], and thus, DLD is a potential therapeutic target.”
BackgroundBlood–Brain Barrier Transport of Alzheimer’s Amyloid β-Peptide
Nelson, A. R., Sagare, A. P., & Zloković, B. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00009-5 · Cited by 12
Investigating Owner Use of Dietary Supplements in Dogs with Canine Cognitive Dysfunction
Haake, J., Meyerhoff, N., Meller, S., Twele, F., Charalambous, M., Wilke, V., & Volk, H. (2023) · Animals · doi:10.3390/ani13193056 · Cited by 9
Wang, K., Yuan, Y., Zhu, B., Zhang, Y., Wei, Y.-F., Meng, F.-S., Zhang, S., Wang, J., Zhou, J., & Initiative, A. D. N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1277731 · Cited by 8
Yu, G.-X., Initiative, A. D. N., Zhang, T., Hou, X., Ou, Y., Hu, H., Wang, Z.-T., Guo, Y., Xu, W., Tan, L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201117 · Cited by 9
“Diminished cerebral glucose metabolism was proved to occur before neurodegenerative changes and cerebral atrophy [38], and it could predict cognitive decline years before clinical diagnosis of AD [39].”
BackgroundFessel, J. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12177 · Cited by 10
Cognitive Impairment and Dementias.
Khosravi, M., Newberg, A., & Alavi, A. (2018) · Seminars in nuclear medicine · doi:10.1053/j.semnuclmed.2018.07.005 · Cited by 8
Blood-brain barrier at the interface of air pollution-associated neurotoxicity and neuroinflammation
Young, T. L., Zychowski, K. E., Denson, J. L., & Campen, M. J. (2018) · Advances in neurotoxicology · doi:10.1016/bs.ant.2018.10.010 · Cited by 11
Gupta, S., Jinka, S. K. A., Khanal, S., Bhavnani, N., Almashhori, F., Lallo, J., Mathias, A., Al‐Rhayyel, Y., Herman, D. E., Holden, J. G., et al. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25196 · Cited by 8
Patil, S. P., & Kuehn, B. R. (2024) · Pharmaceuticals · doi:10.3390/ph17040491 · Cited by 6
“The glucose metabolism is also significantly decreased in patients with mild cognitive impairment (MCI) who subsequently develop AD [18].”
BackgroundThe Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly
Kollack‐Walker, S., Liu, C. Y., & Fleisher, A. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.010 · Cited by 6
Neural Correlates of Executive Dysfunction in Prodromal and Manifest Alzheimer’s Disease
Hunt, A. M., Haberkorn, U., Schröder, J., & Schönknecht, P. (2011) · GeroPsych · doi:10.1024/1662-9647/a000038 · Cited by 5
Self-citationZhang, X., Hao, Y., Zhang, J., Ji, Y., Zou, S.-H., Zhao, S.-J., Xie, S.-Y., & Du, L. (2023) · Comput. Methods Programs Biomed. · doi:10.1016/j.cmpb.2023.107450 · Cited by 4
Newberg, A. B., Coble, R., Khosravi, M., & Alavi, A. A. (2022) · PET Clinics · doi:10.1016/j.cpet.2022.03.009 · Cited by 4
Positron emission tomography in neurological and psychiatric disorders
Newberg, A. B., Monti, D., Moss, A., & Alavi, A. A. (2012) · International Journal of Imaging Systems and Technology · doi:10.1002/ima.22004 · Cited by 3
“More recently, Hunt et al. (2007) investigated metabolicCorrespondence to: Andrew B. Newberg; e-mail: Andrew.newberg@jefferson.edu ' 2012 Wiley Periodicals, Inc. abnormalities in patients with aging-associated cognitive decline (AACD), AD and control, reporting that relative to controls, patients…”
BackgroundAhmad, W., & Shabbiri, K. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02522-3 · Cited by 2
Ahmad, W. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/228429 · Cited by 2
“The first interpretation is mostly supported by studies conducted at a late stage of the disease on postmortem brains, making it difficult to assign causality [13-17].”
BackgroundRaikes, A., Garza, M., Murrell, A. N., & Brinton, R. D. (2026) · medRxiv · doi:10.64898/2026.04.07.26350339 · Cited by 1
Xu, S., Tang, C.-Y., Shi, L., Chen, J., Jia, J., & Qi, J. (2026) · Neurocomputing · doi:10.1016/j.neucom.2026.133697 · Cited by 1
Graph Signal Entropy for Analyzing Functional Brain Abnormalities of Alzheimer’s Disease Patients
Pu, R., Song, X., & Chai, L. (2025) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2025.3620444 · Cited by 1
“…[40], [41] reported the abnormal brain region of inferior temporal gyrus (ROI 28, ROI 29), [42] reported the inferior frontal gyrus (ROI 12), [43], [44] reported the right angular gyrus (ROI 41), [45], [46] reported the frontal medial cortex (ROI 49), and [47] reported the cerebelum (ROI 121).”
Motta, C., Bonomi, C., Poli, M., Mercuri, N., Martorana, A., & Chiaravalloti, A. (2025) · Applied Sciences · doi:10.3390/app15105677 · Cited by 1
Convergence of Accelerated Brain Volume Decline in Normal Aging and Alzheimer’s Disease Pathology
Avelar‐Pereira, B., Phillips, C. M., Hosseini, S. M. H., & Initiative, A. D. N. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231458 · Cited by 1
“37 This could indicate that this region functions as a possible indicator of future AD.”
Flavonoid-Rich Trianthema decandra Ameliorates Cognitive Dysfunction in the Hyperglycemic Rats
Momina, S. S., & Gandla, K. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10744-2 · Cited by 1
“The AD sufferers and those at risk have reduced glucose metabolism in temporal and parietal brain areas are seen in the studies (Mosconi et al. 2005; Hunt et al. 2007; Jacobs et al. 2012).”
Hong, S., Hong, S., & Lee, S. H. (2023) · Animal Cells and Systems · doi:10.1080/19768354.2023.2197761 · Cited by 1
“…positron emission tomography studies have implicated the dysregulation of brain glucose uptake is associated with AD pathology (Mosconi 2005, Hunt et al. 2007), and impaired glucose metabolism and glycolytic fl ux in brains were also related to A β deposition and severity of AD (An et al.…”
BackgroundÖstrogene und Alzheimer-Demenz
Schönknecht, P., & Schröder, J. (2011) · Gynäkologische Endokrinologie · doi:10.1007/s10304-010-0389-3 · Cited by 1
Self-citationIn Vitro Blood-Brain Barrier Functional Assays in a Human iPSC-Based Model
Neal, E., Shi, Y., & Lippmann, E. (2019) · Neuromethods · doi:10.1007/978-1-4939-9228-7_1 · Cited by 1
Ahmed, H. M., Al‐Hussainy, A. F., Arora, V., Rekha, M. M., Kundlas, M., Chennakesavulu, K., Manu, M., Rizaev, J., Taher, S. G., Alwan, M., et al. (2026) · Brain Imaging and Behavior · doi:10.1007/s11682-026-01181-3
“By the time AD is diagnosed, the brain’s metabolic dysregulation, as evidenced by decreased cerebral glucose metabolism (Kumar et al. 2022, Hunt et al. 2007), may have reached a level where the impact on synaptic function is no longer as directly measurable by GAP-43 alone.”
Saiyad, S. S., Rajput, J., Horo, S. M., Kumari, K., Biswas, P. C., Ekambaram, G., Chouhan, A., & Ranga, S. (2026) · Cureus · doi:10.7759/cureus.106239
“Among these, cerebral glucose hypometabolism has emerged as one of the earliest and most consistent biological abnormalities observed in AD [8-10].”
Stocks, J. K., Initiative, A. D. N., Heywood, A. A., Popuri, K., Beg, M. F., Rosen, H. J., & Wang, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220975
Inhibiting PI3K leads to glucose metabolism disturbance in default mode network
Hao, J., Tang, Y., Liu, X., & Yao, E. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.02.020
Ahmad, W. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/228437 · Cited by 1
Metabolic study of Alzheimer’s disease using mutant C. elegans
Ahmad, W. (2017) · The University of Queensland · doi:10.14264/uql.2017.500
“44 interpretation is mostly supported by studies conducted at a late stage of the disease on post-mortem brains, making it difficult to assign causality [205, 434-437].”
BackgroundO4‐01‐02: Meta‐analytic comparison of PiB‐PET and FDG‐PET results in Alzheimer's disease and MCI
He, W., Xu, J., Shi, J.-Q., & Radua, J. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.1635
“Regarding FDG-PET, 24 studies in patients with AD met the criteria [20, 21, 23, 25–45], though eight publications [25–27, 31, 32, 34–36] had to be excluded because they contained overlapped datasets or lacked key information.”
BackgroundKlinik und bildgebende Diagnostik neurodegenerativer Demenzen
Schönknecht, P., Sattler, C., Toro, P., & Essig, M. (2011) · Der Radiologe · doi:10.1007/s00117-010-2092-8
Self-citationAn Infectious Origin of Alzheimer’s Disease: An End for This Devastating Disorder?
Miklossy, J., & Fulop, T. (2020) · Frontiers Research Topics · doi:10.3389/978-2-88963-903-8
“Cerebral glucose metabolism is decreased in preclinical and prodromal AD before symptoms (Hunt et al., 2007; Herholz, 2010).”
BackgroundBlood-brain barrier impairment in neurodegeneration
Palejko, A., & Członkowska, A. (2020) · doi:10.5114/nan.2020.93224
“Aβ(1-42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins.”
BackgroundSindi, S., Rosenberg, A., Juster, R., & LUPIEN, S. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00082-1 · Cited by 1
Metadata
- Authors
- Hunt, A., Schönknecht, P., Henze, M., Seidl, U., Haberkorn, U., & Schröder, J.
- Affiliations
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Schröder, Johannes
- ORCID
- Schröder, Johannes
- Venue
- Psychiatry Research: Neuroimaging
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 155
- Issue
- 2
- Pages
- 147-154
- ISSN
- 0925-4927 (ISSN-L)
- OpenAlex
- W2037603765
- Cited by
- 146
- References
- 41
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 9 · 2023: 16 · 2022: 5 · 2021: 9 · 2020: 6 · 2019: 9 · 2018: 9 · 2017: 7 · 2016: 10 · 2015: 5 · 2014: 5 · 2013: 4 · 2012: 8
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatry Research Neuroimaging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, brain glucose metabolism, mild cognitive impairment, conversion to Alzheimer's disease, precuneus, posterior cingulate cortex, angular gyrus, middle temporal cortex, frontal cortex, thalamus, FDG-PET
- MeSH terms
- Aged, Alzheimer Disease, Brain, Brain Mapping, Cerebral Cortex, Cognition Disorders, Female, Follow-Up Studies, Frontal Lobe, Glucose, Gyrus Cinguli, Humans, Image Processing, Computer-Assisted, Functional Laterality, Male, Severity of Illness Index, Temporal Lobe, Tissue Distribution, Disease Progression, Fluorodeoxyglucose F18, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
